Dacarbazine
Above: molecular structure of dacarbazine
Below: 3D representation of a dacarbazine molecule | |
| Clinical data | |
|---|---|
| Pronunciation | /dəˈkɑːrbəˌziːn/ |
| Trade names | DTIC-Dome, others |
| Other names | DTIC[1] |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a682750 |
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 100% |
| Metabolism | Extensive |
| Elimination half-life | 5 hours |
| Excretion | Kidney (40% as unchanged dacarbazine) |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| ECHA InfoCard | 100.022.179 |
| Chemical and physical data | |
| Formula | C6H10N6O |
| Molar mass | 182.187 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (what is this?) (verify) | |
Dacarbazine, also known as imidazole carboxamide and sold under the brand name DTIC-Dome, is a chemotherapy medication used in the treatment of melanoma and Hodgkin's lymphoma.[2] For Hodgkin's lymphoma, it is often used together with vinblastine, bleomycin, and doxorubicin.[2] It is given by injection into a vein.[2]
Common side effects include loss of appetite, vomiting, low white blood cell count, and low platelets.[2] Other serious side effects include liver problems and allergic reactions.[2] It is unclear if use in pregnancy is safe for the baby.[2] Dacarbazine is in the alkylating agent and purine analog families of medication.[2]
Dacarbazine was approved for medical use in the United States in 1975.[2] It is on the World Health Organization's List of Essential Medicines.[3]
- ^ Elks J, Ganellin CR, eds. (1990). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 344–. doi:10.1007/978-1-4757-2085-3. ISBN 978-1-4757-2087-7.
- ^ a b c d e f g h "Dacarbazine". The American Society of Health-System Pharmacists. Archived from the original on September 11, 2017. Retrieved December 8, 2016.
- ^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.